Clinical trials: Depressive State
Major Depressive Disorder
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
The current study will evaluate the antidepressant effect of CERC-301 during 28 days of treatment in subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with selective…
- Trial name
- NCT01941043
- Testing
- CERC-301
- Where
- 24 sites in United States
- Volunteers
- 1,357 people
- Sponsor
- Avalo Therapeutics, Inc.
Depressive Disorder, Major
Study for Evaluating Different Methods of Measuring Depression Treatment Response
Purpose of the study is to evaluate use of electronic diaries and voice acoustics for use in future depression clinical trial. Focus is on increased precision of measurement.
- Trial name
- NCT00406952
- Testing
- electronic diary, Sertraline, voice acoustics
- Where
- 12 sites in United States
- Volunteers
- 165 people
- Sponsor
- Pfizer
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
- Trial name
- NCT02085135
- Testing
- ALKS 5461
- Where
- 9 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Depression, Pain
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side…
- Trial name
- NCT00036335
- Testing
- Duloxetine Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eli Lilly and Company
Perinatal Depression
Responsive e-Health Intervention for Perinatal Depression in Healthcare Settings
Perinatal depression is experienced by at least 14-20% of pregnant and postpartum women, and is recognized as the most common complication of childbirth.
- Trial name
- MMB (NCT03995316)
- Testing
- Treatment As Usual + MMB 2.0, Treatment As Usual Only
- Where
- 2 sites in United States
- Volunteers
- 191 people
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Major Depressive Disorder
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®.
- Trial name
- NCT01369030
- Testing
- Deplin®
- Where
- 2 sites in United States
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
Depression
To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets
To demonstrate the relative bioequivalency of comparing single 100 mg doses Of Cord's 50 mg Desipramine Hcl tablets to Merrell Dow's 50 mg Norpramin tablets.
- Trial name
- NCT00914004
- Testing
- Desipramine HCl 50 mg Tablets Cord Laboratories, Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Bipolar Disorder, Bipolar Depression
Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy
Prospective, open-label, controlled (active comparator), randomized study of 8 weeks follow-up for the evaluation of the efficacy of extended release quetiapine (quetiapine XR) versus Sertraline in addition to previous mood…
- Trial name
- NCT00857584
- Testing
- Extended release quetiapine (quetiapine XR), Sertraline, adequate mood stabilizer
- Where
- 4 sites in Spain
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Depression
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
- Trial name
- NCT01361555
- Testing
- BMS-820836
- Where
- 144 sites in United States, Argentina and 10 more
- Volunteers
- 789 people
- Sponsor
- Bristol-Myers Squibb
Depressive Disorder, Major
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
To assess the effect of a single dose of BI 1358894 compared to placebo on BOLD responses in modulating brain processing of emotional and cognitive stimuli on the amygdala and related brain structure using fMRI in in unmedicated…
- Trial name
- NCT03854578
- Testing
- BI 1358894, Citalopram
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Anxiety Depression
Efficacy and Safety of Probiotics for Anxiety Depression
This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the…
- Trial name
- NCT07331987
- Testing
- Probiotic, Escitalopram
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Moon (Guangzhou) Biotechnology Co., Ltd.
Anxiety, Depression
A Randomized-Controlled Trial to Investigate the Effect of a Novel Music Therapy Application to Reduce Anxiety and Stress
This virtual, open-label, three-group, randomized-controlled trial will last six weeks. Participants will be allocated into three groups; the Intervention Group, Spotify Group, and Control Group.
- Conditions
- Anxiety, Depression, Stress
- Trial name
- NCT06021821
- Testing
- SoundMind App, Spotify Playlist
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- SoundMind
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Perinatal Depression, Specific Phobia
Maternal Telemental Health Interventions in Response to Covid-19*
The purpose of this study is to assess the effectiveness of a telemental health intervention on the mental health of pregnant women during the COVID-19 crisis in Qatar.
- Conditions
- Perinatal Depression, Specific Phobia, Perinatal Anxiety
- Trial name
- CoronaVirus (NCT04594525)
- Testing
- Low-Intensity Psychosocial Interventions through Telemental health
- Where
- Qatar
- Volunteers
- 58 people
- Sponsor
- Hamad Medical Corporation
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Depression
Effect of a Single Virtual Reality Exposure on Depressive Symptoms (Veovita-VR)
The trial aims to evaluate the effectiveness of a novel virtual reality (VR) intervention (Veovita-VR) designed to expose people with at least moderate depressive symptoms to positive emotional stimuli and positive behavioral…
- Trial name
- NCT05529797
- Testing
- Veovita-VR
- Where
- Germany
- Volunteers
- 128 people
- Sponsor
- Gaia AG